{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:09:31Z","timestamp":1771398571078,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,17]]},"DOI":"10.7759\/cureus.103809","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:08:06Z","timestamp":1771394886000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Adverse Events Associated With Six Common Antibiotics in Lower Respiratory Tract Infections Using the United States Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.7759","author":[{"given":"Toru","family":"Ogura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1028525","article-title":"Global burden of lower respiratory infections during the last three decades","volume":"10","author":"Safiri S","year":"2022","unstructured":"Safiri S, Mahmoodpoor A, Kolahi AA, et al.. Global burden of lower respiratory infections during the last three decades. Front Public Health. 2022, 10:1028525. 10.3389\/fpubh.2022.1028525","journal-title":"Front Public Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.67685","article-title":"Clinical, biological, and radiological findings and management of lower respiratory tract infections in a tertiary hospital in Romania","volume":"16","author":"Bulata-Pop I","year":"2024","unstructured":"Bulata-Pop I, Stirbu I, Simionescu B, Grama A, Junie LM. Clinical, biological, and radiological findings and management of lower respiratory tract infections in a tertiary hospital in Romania. Cureus. 2024, 16:e67685. 10.7759\/cureus.67685","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.61924","article-title":"Evaluating the sputum bacteriological profile of lower respiratory tract infections with Bartlett score analysis in a tertiary care hospital in southern Karnataka","volume":"16","author":"Mahale RP","year":"2024","unstructured":"Mahale RP, Darpan Sheth P, Murthy NS. Evaluating the sputum bacteriological profile of lower respiratory tract infections with Bartlett score analysis in a tertiary care hospital in southern Karnataka. Cureus. 2024, 16:e61924. 10.7759\/cureus.61924","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03672.x","article-title":"Guidelines for the management of adult lower respiratory tract infections--full version","volume":"17 Suppl 6","author":"Woodhead M","year":"2011","unstructured":"Woodhead M, Blasi F, Ewig S, et al.. Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect. 2011, 17 Suppl 6:E1-59. 10.1111\/j.1469-0691.2011.03672.x","journal-title":"Clin Microbiol Infect"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1305294","article-title":"Antibiotic action and resistance: updated review of mechanisms, spread, influencing factors, and alternative approaches for combating resistance","volume":"14","author":"Halawa EM","year":"2023","unstructured":"Halawa EM, Fadel M, Al-Rabia MW, et al.. Antibiotic action and resistance: updated review of mechanisms, spread, influencing factors, and alternative approaches for combating resistance. Front Pharmacol. 2023, 14:1305294. 10.3389\/fphar.2023.1305294","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.suppl_e.153","article-title":"Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection","volume":"31 Suppl E","author":"Bradbury F","year":"1993","unstructured":"Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. J Antimicrob Chemother. 1993, 31 Suppl E:153-62. 10.1093\/jac\/31.suppl_e.153","journal-title":"J Antimicrob Chemother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00735-6","article-title":"Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial","volume":"23","author":"Tsalik EL","year":"2023","unstructured":"Tsalik EL, Rouphael NG, Sadikot RT, et al.. Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial. Lancet Infect Dis. 2023, 23:484-95. 10.1016\/S1473-3099(22)00735-6","journal-title":"Lancet Infect Dis"},{"key":"ref8","unstructured":"FDA Adverse Event Reporting System (FAERS) quarterly data. (2026). Accessed. January 31, 2026: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2234825","article-title":"Seizures associated with antibiotics: a real-world disproportionality analysis of FAERS database","volume":"22","author":"Zou D","year":"2023","unstructured":"Zou D, Zhang R, Yu L, Hu T, Wu B. Seizures associated with antibiotics: a real-world disproportionality analysis of FAERS database. Expert Opin Drug Saf. 2023, 22:1143-8. 10.1080\/14740338.2023.2234825","journal-title":"Expert Opin Drug Saf"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00873-8","article-title":"Comparing acute kidney injury reports among antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)","volume":"43","author":"Patek TM","year":"2020","unstructured":"Patek TM, Teng C, Kennedy KE, Alvarez CA, Frei CR. Comparing acute kidney injury reports among antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Drug Saf. 2020, 43:17-22. 10.1007\/s40264-019-00873-8","journal-title":"Drug Saf"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01242-7","article-title":"Comparison of adverse events occurred during administration of dipeptidyl peptidase-4 inhibitor in patients with diabetes using FDA Adverse Event Reporting System","volume":"43","author":"Ogura T","year":"2023","unstructured":"Ogura T, Shiraishi C. Comparison of adverse events occurred during administration of dipeptidyl peptidase-4 inhibitor in patients with diabetes using FDA Adverse Event Reporting System. Clin Drug Investig. 2023, 43:129-40. 10.1007\/s40261-022-01242-7","journal-title":"Clin Drug Investig"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81260","article-title":"Comparative analysis of adverse event profiles among seven statins for hypercholesterolemia management using the United States FDA Adverse Event Reporting System","volume":"17","author":"Ogura T","year":"2025","unstructured":"Ogura T, Shiraishi C. Comparative analysis of adverse event profiles among seven statins for hypercholesterolemia management using the United States FDA Adverse Event Reporting System. Cureus. 2025, 17:e81260. 10.7759\/cureus.81260","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-019-0754-4","article-title":"Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomes","volume":"19","author":"Vickerstaff V","year":"2019","unstructured":"Vickerstaff V, Omar RZ, Ambler G. Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomes. BMC Med Res Methodol. 2019, 19:129. 10.1186\/s12874-019-0754-4","journal-title":"BMC Med Res Methodol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3201\/eid1508.081187","article-title":"Increase in pneumococcus macrolide resistance, United States","volume":"15","author":"Jenkins SG","year":"2009","unstructured":"Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis. 2009, 15:1260-4. 10.3201\/eid1508.081187","journal-title":"Emerg Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab538","article-title":"Ambulatory fluoroquinolone use in the United States, 2015-2019","volume":"8","author":"Umarje SP","year":"2021","unstructured":"Umarje SP, Alexander CG, Cohen AJ. Ambulatory fluoroquinolone use in the United States, 2015-2019. Open Forum Infect Dis. 2021, 8:ofab538. 10.1093\/ofid\/ofab538","journal-title":"Open Forum Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky306","article-title":"Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?","volume":"73","author":"Russell AH","year":"2018","unstructured":"Russell AH, Horner C, Livermore DM, MacGowan AP. Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?. J Antimicrob Chemother. 2018, 73:3212-5. 10.1093\/jac\/dky306","journal-title":"J Antimicrob Chemother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2009.011","article-title":"The odds ratio: calculation, usage, and interpretation","volume":"19","author":"McHugh ML","year":"2009","unstructured":"McHugh ML. The odds ratio: calculation, usage, and interpretation. Biochem Med. 2009, 19:120-6. 10.11613\/BM.2009.011","journal-title":"Biochem Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222690","article-title":"A method of back-calculating the log odds ratio and standard error of the log odds ratio from the reported group-level risk of disease","volume":"15","author":"Hu D","year":"2020","unstructured":"Hu D, Wang C, O'Connor AM. A method of back-calculating the log odds ratio and standard error of the log odds ratio from the reported group-level risk of disease. PLoS One. 2020, 15:e0222690. 10.1371\/journal.pone.0222690","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0729-y","article-title":"Relative and absolute risk of tendon rupture with fluoroquinolone and concomitant fluoroquinolone\/corticosteroid therapy: population-based nested case-control study","volume":"39","author":"Morales DR","year":"2019","unstructured":"Morales DR, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X. Relative and absolute risk of tendon rupture with fluoroquinolone and concomitant fluoroquinolone\/corticosteroid therapy: population-based nested case-control study. Clin Drug Investig. 2019, 39:205-13. 10.1007\/s40261-018-0729-y","journal-title":"Clin Drug Investig"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2389","article-title":"Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds","volume":"41","author":"Kashida Y","year":"1997","unstructured":"Kashida Y, Kato M. Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds. Antimicrob Agents Chemother. 1997, 41:2389-93. 10.1128\/AAC.41.11.2389","journal-title":"Antimicrob Agents Chemother"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2010.10.003","article-title":"Musculoskeletal complications of fluoroquinolones: guidelines and precautions for usage in the athletic population","volume":"3","author":"Hall MM","year":"2011","unstructured":"Hall MM, Finnoff JT, Smith J. Musculoskeletal complications of fluoroquinolones: guidelines and precautions for usage in the athletic population. PM R. 2011, 3:132-42. 10.1016\/j.pmrj.2010.10.003","journal-title":"PM R"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1437376","article-title":"Safety analysis of quinolones use in minors-based on the FAERS database","volume":"11","author":"Li Y","year":"2024","unstructured":"Li Y, Wang J, Wang C, Chen L. Safety analysis of quinolones use in minors-based on the FAERS database. Front Med (Lausanne). 2024, 11:1437376. 10.3389\/fmed.2024.1437376","journal-title":"Front Med (Lausanne)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh110","article-title":"Diffusion of levofloxacin into bone and synovial tissues","volume":"53","author":"Rimmel\u00e9 T","year":"2004","unstructured":"Rimmel\u00e9 T, Boselli E, Breilh D, et al.. Diffusion of levofloxacin into bone and synovial tissues. J Antimicrob Chemother. 2004, 53:533-5. 10.1093\/jac\/dkh110","journal-title":"J Antimicrob Chemother"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10101144","article-title":"Antibiotic-related adverse drug reactions in patients treated on the dermatology ward of Medical University of Gda\u0144sk","volume":"10","author":"Sokolewicz EM","year":"2021","unstructured":"Sokolewicz EM, Rogowska M, Lewandowski M, Puchowska M, Piechota D, Bara\u0144ska-Rybak W. Antibiotic-related adverse drug reactions in patients treated on the dermatology ward of Medical University of Gda\u0144sk. Antibiotics (Basel). 2021, 10:10.3390\/antibiotics10101144","journal-title":"Antibiotics (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2010.08.014","article-title":"Clarithromycin-induced neurotoxicity in adults","volume":"18","author":"Bandettini di Poggio M","year":"2011","unstructured":"Bandettini di Poggio M, Anfosso S, Audenino D, Primavera A. Clarithromycin-induced neurotoxicity in adults. J Clin Neurosci. 2011, 18:313-8. 10.1016\/j.jocn.2010.08.014","journal-title":"J Clin Neurosci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1547","article-title":"Adverse events associated with prolonged antibiotic use","volume":"17","author":"Meropol SB","year":"2008","unstructured":"Meropol SB, Chan KA, Chen Z, et al.. Adverse events associated with prolonged antibiotic use. Pharmacoepidemiol Drug Saf. 2008, 17:523-32. 10.1002\/pds.1547","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw054","article-title":"Gender differences in antibiotic prescribing in the community: a systematic review and meta-analysis","volume":"71","author":"Schr\u00f6der W","year":"2016","unstructured":"Schr\u00f6der W, Sommer H, Gladstone BP, Foschi F, Hellman J, Evengard B, Tacconelli E. Gender differences in antibiotic prescribing in the community: a systematic review and meta-analysis. J Antimicrob Chemother. 2016, 71:1800-6. 10.1093\/jac\/dkw054","journal-title":"J Antimicrob Chemother"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020203","article-title":"Understanding the gender gap in antibiotic prescribing: a cross-sectional analysis of English primary care","volume":"8","author":"Smith DR","year":"2018","unstructured":"Smith DR, Dolk FC, Smieszek T, Robotham JV, Pouwels KB. Understanding the gender gap in antibiotic prescribing: a cross-sectional analysis of English primary care. BMJ Open. 2018, 8:e020203. 10.1136\/bmjopen-2017-020203","journal-title":"BMJ Open"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2024-016711","article-title":"Understanding gender inequities in antimicrobial resistance: role of biology, behaviour and gender norms","volume":"10","author":"Batheja D","year":"2025","unstructured":"Batheja D, Goel S, Charani E. Understanding gender inequities in antimicrobial resistance: role of biology, behaviour and gender norms. BMJ Glob Health. 2025, 10:10.1136\/bmjgh-2024-016711","journal-title":"BMJ Glob Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/465163-comparison-of-adverse-events-associated-with-six-common-antibiotics-in-lower-respiratory-tract-infections-using-the-united-states-food-and-drug-administration-adverse-event-reporting-system","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:08:07Z","timestamp":1771394887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/465163-comparison-of-adverse-events-associated-with-six-common-antibiotics-in-lower-respiratory-tract-infections-using-the-united-states-food-and-drug-administration-adverse-event-reporting-system"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.103809","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,17]]}}}